Glycosaminoglycans: Key players in cancer cell biology and treatment

FEBS Journal

Volumn 279, Issue 7, 2012, Pages 1177-1197

  Afratis, Nikos ^a   Gialeli, Chrisostomi ^a,b   Nikitovic, Dragana ^c   Tsegenidis, Theodore ^a   Karousou, Evgenia ^d   Theocharis, Achilleas D ^a   Pavão, Mauro S ^e   Tzanakakis, George N ^c   Karamanos, Nikos K ^a,b  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

cancer progression; chondroitin sulfate; extracellular matrix; glycosaminoglycans; heparan sulfate; hyaluronan; pharmacological targeting

Indexed keywords

BETA CATENIN; CD44V6 ANTIBODY CYTOTOXIN CONJUGATE; CHONDROITIN SULFATE; DALTEPARIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; GALLIC ACID; GLYCOSAMINOGLYCAN; GLYPICAN; HEPARANASE; HEPARIN; HEPARIN DERIVATIVE; HYALURONIC ACID; HYMECROMONE; IMMUNOTOXIN; LOW MOLECULAR WEIGHT HEPARIN; PI 88; PROTEOHEPARAN SULFATE; QUERCETIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; STAT5B PROTEIN; SURAMIN; SYNDECAN 4; ULTRA LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; CELL FUNCTION; CELL PROLIFERATION; CYTOLOGY; DRUG POTENCY; DRUG TARGETING; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SULFATION;

CHONDROITIN SULFATES; DISEASE PROGRESSION; GLYCOSAMINOGLYCANS; HUMANS; HYALURONIC ACID; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 84859102182     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08529.x     Document Type: Review

References (178)

1. Iozzo RV, &, Karamanos NK, (2010) Proteoglycans in health and disease: emerging concepts and future directions. FEBS J 277, 3863.
2. Theocharis AD, Skandalis SS, Tzanakakis GN, &, Karamanos NK, (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
3. Hascall V, &, Karamanos NK, (2011) Regulatory roles of hyaluronan in health and disease. FEBS J 278, 1411.
4. Duchez S, Pascal V, Cogné N, Jayat-Vignoles C, Julien R, &, Cogné M, (2011) Glycotranscriptome study reveals an enzymatic switch modulating glycosaminoglycan synthesis during B-cell development and activation. Eur J Immunol 41, 3632-3644.
5. Karamanos NK, Syrokou A, Vanky P, Nurminen M, &, Hjerpe A, (1994) Determination of 24 variously sulfated galactosaminoglycan- and hyaluronan-derived disaccharides by high-performance liquid chromatography. Anal Biochem 221, 189-199.
6. Malavaki C, Mizumoto S, Karamanos NK, &, Sugahara K, (2008) Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res 49, 133-139.
7. Karamanos NK, Vanky P, Tzanakakis GN, Tsegenidis T, &, Hjerpe A, (1997) Ion-pair high-performance liquid chromatography for determining disaccharide composition in heparin and heparan sulphate. J Chromatogr A 765, 169-179.
8. Militsopoulou M, Lamari FN, Hjerpe A, &, Karamanos NK, (2002) Determination of twelve heparin- and heparan sulfate-derived disaccharides as 2-aminoacridone derivatives by capillary zone electrophoresis using ultraviolet and laser-induced fluorescence detection. Electrophoresis 23, 1104-1109.
9. Malavaki CJ, Theocharis AD, Lamari FN, Kanakis I, Tsegenidis T, Tzanakakis GN, &, Karamanos NK, (2011) Heparan sulfate: biological significance, tools for biochemical analysis and structural characterization. Biomed Chromatogr 25, 11-20.
10. Esko JD, &, Lindahl U, (2001) Molecular diversity of heparan sulfate. J Clin Invest 108, 169-173.
11. Sasisekharan R, Shriver Z, Venkataraman G, &, Narayanasami U, (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2, 521-528.
12. Lindahl U, &, Li JP, (2009) Interactions between heparan sulfate and proteins-design and functional implications. Inter Rev Cell Mol Biol 276, 105-159.
13. Timpl R, &, Brown JC, (1996) Supramolecular assembly of basement membranes. BioEssays 18, 123-132.
14. Sanderson RD, (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12, 89-98.
15. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, &, Klagsbrun M, (1987) Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84, 2292-2296.
16. Gallagher JT, (2001) Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 108, 357-361.
17. Guimond S, Maccarana M, Olwin BB, Lindahl U, &, Rapraeger AC, (1993) Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 268, 23906-23914.
18. Nikitovic D, Assouti M, Sifaki M, Katonis P, Krasagakis K, Karamanos NK, &, Tzanakakis GN, (2008) Chondroitin sulfate and heparan sulfate-containing proteoglycans are both partners and targets of basic fibroblast growth factor-mediated proliferation in human metastatic melanoma cell lines. Int J Biochem Cell Biol 40, 72-83.
19. Faham S, Linhardt RJ, &, Rees DC, (1998) Diversity does make a difference: fibroblast growth factor-heparin interactions. Curr Opin Struct Biol 8, 578-586.
20. Lindahl U, Kusche-Gullberg M, &, Kjellen L, (1998) Regulated diversity of heparan sulfate. J Biol Chem 273, 24979-24982.
21. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, &, Zhang L, (1997) Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest 99, 2062-2070.
22. Mundhenke C, Meyer K, Drew S, &, Friedl A, (2002) Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 160, 185-194.
23. Chalkiadaki G, Nikitovic D, Berdiaki A, Sifaki M, Krasagakis K, Katonis P, Karamanos NK, &, Tzanakakis GN, (2009) Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. Int J Biochem Cell Biol 41, 1323-1331.
24. Zittermann SI, Capurro MI, Shi W, &, Filmus J, (2010) Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 126, 1291-1301.
25. Kim SH, Turnbull J, &, Guimond S, (2011) Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 209, 139-151.
26. Moustakas A, &, Heldin CH, (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98, 1512-1520.
27. Bishop JR, Schuksz M, &, Esko JD, (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037.
28. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Müller GA, &, Neilson EG, (2002) Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 61, 1714-1728.
29. Corso S, Comoglio PM, &, Giordano S, (2005) Cancer therapy: can the challenge be MET? Trends Mol Med 11, 284-292.
30. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, &, Parish CR, (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5, 803-809.
31. Vlodavsky I, &, Friedmann Y, (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108, 341-347.
32. Elkin M, &, Vlodavsky I, (2001) Tail vein assay of cancer metastasis. Curr Protoc Cell Biol, Chapter 19, Unit 19.2.
33. Luan G, Sun J, Li G, Zhang G, Lv Y, Wang G, Li C, Ma C, &, Gao T, (2011) Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression. Cancer Lett 308, 100-111.
34. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, &, Ilan N, (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66, 1455-1463.
35. Cohen-Kaplan V, Jrbashyan J, Yanir Y, Naroditsky I, Ben-Izhak O, Ilan N, Doweck I, &, Vlodavsky I, (2012) Heparanase induces STAT protein phosphorylation: pre-clinical and clinical significance in head and neck cancer. J Biol Chem 287, 6668-6678.
36. Ridgway LD, Wetzel MD, &, Marchetti D, (2011) Heparanase modulates Shh and Wnt3a signaling in human medulloblastoma cells. Exp Ther Med 2, 229-238.
37. Ramani VC, Yang Y, Ren Y, Nan L, &, Sanderson RD, (2011) Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem 286, 6490-6949.
38. Chen L, &, Sanderson R, (2009) Heparanase regulates levels of syndecan-1 in the nucleus. PLoS ONE 4, e4947.
39. Fedarko NS, Ishihara M, &, Conrad HE, (1989) Control of cell division in hepatoma cells by exogenous heparan sulfate proteoglycan. J Cell Physiol 139, 287-294.
40. Kovalszky I, Dudás J, Oláh-Nagy J, Pogány G, Töváry J, Timár J, Kopper L, Jeney A, &, Iozzo RV, (1998) Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Mol Cell Biochem 183, 11-23.
41. Buczck-Thomas JA, Hsia E, Rich CB, Foster JA, &, Nugent MA, (2008) Inhibition of histone acetyltransferase by glycosaminoglycans. J Cell Biochem 105, 108-120.
42. Hsia E, Richardson TP, &, Nugent MA, (2003) Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling. J Cell Biochem 88, 1214-1225.
43. Brobkstedt U, Dobra K, Nurminen M, &, Hjerpe A, (2002) Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements. Exp Cell Res 274, 235-245.
44. Zong F, Fthenou E, Wolmer N, Hollõsi P, Kovalszky I, Szilák L, Mogler C, Nilsonne G, Tzanakakis G, &, Dobra K, (2009) Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. PLoS ONE 4, e7346.
45. Fedarko NS, &, Conrad HE, (1986) A unique heparan sulfate in the nuclei of hepatocytes: structural changes with the growth state of the cells. J Cell Biochem 102, 587-599.
46. Ishihara M, Fedarko NS, &, Conrad HE, (1986) Transport of heparan sulfate into the nuclei of hepatocytes. J Biol Chem 261, 13575-13580.
47. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, &, Shridhar V, (2003) Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278, 23107-23117.
48. Khurana A, Liu P, Mellone P, Lorenzon L, Vincenzi B, Datta K, Yang B, Linhardt RJ, Lingle W, Chien J, et al. (2011) HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res 71, 2152-2161.
49. Narita K, Chien J, Mullany SA, Staub J, Qian X, Lingle WL, &, Shridhar V, (2007) Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 282, 14413-14420.
50. Li J, Mo ML, Chen Z, Yang J, Li QS, Wang DJ, Zhang H, Ye YJ, Li HL, Zhang F, et al. (2011) HSulf-1 inhibits cell proliferation and invasion in human gastric cancer. Cancer Sci 102, 1815-1821.
51. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, &, Rosen SD, (2010) Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 29, 635-646.
52. Peterson SM, Iskenderian A, Cook L, Romashko A, Tobin K, Jones M, Norton A, Gõmez-Yafal A, Heartlein MW, Concino MF, et al. (2010) Human sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts. BMC Cancer 10, 427.
53. Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, et al. (2010) Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 30, 1522-1528.
54. Schrage YM, Hameetman L, Szuhai K, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, &, Bovee JV, (2009) Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. Am J Pathol 174, 979-988.
55. Reijmers RM, Groen RW, Rozemuller H, Kuil A, de Haan-Kramer A, Csikõs T, Martens AC, Spaargaren M, &, Pals ST, (2010) Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 115, 601-604.
56. Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E, Korc M, Vlodavsky I, Bovin NV, &, Porgador A, (2004) Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 173, 2392-2401.
57. Linhardt RJ, (2003) 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. J Med Chem 46, 2551-2564.
58. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, &, Vlodavsky I, (1987) Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 70, 551-557.
59. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, &, Bevilacqua MP, (1993) Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82, 3253-3258.
60. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C, Johnstone K, Karoli T, Davis K, Copeman E, et al. (2007) PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 33, 557-568.
61. Borsig L, Vlodavsky I, Ishai-Michaeli R, Torri G, &, Vismara E, (2011) Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia 13, 445-452.
62. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, et al. (2011) M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 6, e21106.
63. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, et al. (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17, 1382-1393.
64. Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM, &, Elalamy I, (2008) Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 36, 204-211.
65. Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, Mousa S, Linhardt RJ, &, Liu J, (2011) Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins. Science 334, 498-501.
66. Lindhardt RJ, &, Liu J, (2012) Synthetic heparin. Curr Opin Pharmacol, doi:.
67. Zhou X, Chandarajoti K, Pham TQ, Liu R, &, Liu J, (2011) Expression of heparan sulfate sulfotransferases in Kluyveromyces lactis and preparation of 3′-phosphoadenosine-5′-phosphosulfate. Glycobiology 21, 771-780.
68. Schick BP, Maslow D, Moshinski A, &, San Antonio JD, (2004) Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Blood 103, 1356-1363.
69. Wang J, &, Rabenstein DL, (2006) Interaction of heparin with two synthetic peptides that neutralize the anticoagulant activity of heparin. Biochemistry 45, 15740-15747.
70. Botta M, Manetti F, &, Corelli F, (2000) Fibroblast growth factors and their inhibitors. Curr Pharm Des 6, 1897-1924.
71. Marchetti D, Reiland J, Erwin B, &, Roy M, (2003) Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogue. Int J Cancer 104, 167-174.
72. Liu D, Shriver Z, Qi Y, Venkataraman G, &, Sasisekharan R, (2002) Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin Thromb Hemost 28, 67-78.
73. Liu P, Gou M, Yi T, Xie C, Qi X, Zhou S, Deng H, Wei Y, &, Zhao X, (2011) Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels. Oncol Rep 27, 363-370.
74. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, &, Veerkamp JH, (1998) Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273, 12960-12966.
75. Dennissen MA, Jenniskens GJ, Pieffers M, Versteeg EM, Petitou M, Veerkamp JH, &, van Kuppevelt TH, (2002) Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J Biol Chem 277, 10982-10986.
76. 3, common in heparin, has a strict topography and is involved in cell behavior and disease. J Biol Chem 285, 41143-41151.
77. Welch JE, Bengtson P, Svensson K, Wittrup A, Jenniskens GJ, Ten Dam GB, Van Kuppevelt TH, &, Belting M, (2008) Single chain fragment anti-heparan sulfate antibody targets the polyamine transport system and attenuates polyamine-dependent cell proliferation. Int J Oncol 32, 749-756.
78. Karamanos NK, Vanky P, Syrokou A, &, Hjerpe A, (1995) Identity of dermatan and chondroitin sequences in dermatan sulfate chains determined by using fragmentation with chondroitinases and ion-pair high-performance liquid chromatography. Anal Biochem 225, 220-230.
79. Lamari FN, &, Karamanos NK, (2006) Structure of chondroitin sulfate. Adv Pharmacol 53, 33-48.
80. Asimakopoulou AP, Theocharis AD, Tzanakakis GN, &, Karamanos NK, (2008) The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo 22, 385-389.
81. Theocharis AD, Tsolakis I, Tzanakakis GN, &, Karamanos NK, (2006) Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression. Adv Pharmacol 53, 281-295.
82. Labropoulou VT, Theocharis AD, Ravazoula P, Perimenis P, Hjerpe A, Karamanos NK, &, Kalofonos HP, (2006) Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumors. Histopathology 49, 582-593.
83. Skandalis SS, Labropoulou VT, Ravazoula P, Likaki-Karatza E, Dobra K, Kalofonos HP, Karamanos NK, &, Theocharis AD, (2011) Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer 11, 314.
84. Deepa SS, Umehara Y, Higashiyama S, Itoh N, &, Sugahara K, (2002) Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. J Biol Chem 277, 43707-43716.
85. Ten Dam GB, van de Westerlo EM, Purushothaman A, Stan RV, Bulten J, Sweep FC, Massuger LF, Sugahara K, &, van Kuppevelt TH, (2007) Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. Am J Pathol 171, 1324-1333.
86. Li F, Ten Dam GB, Murugan S, Yamada S, Hashiguchi T, Mizumoto S, Oguri K, Okayama M, van Kuppevelt TH, &, Sugahara K, (2008) Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J Biol Chem 283, 34294-34304.
87. Basappa X, Murugan S, Sugahara KN, Lee CM, Ten Dam GB, van Kuppevelt TH, Miyasaka M, Yamada S, &, Sugahara K, (2009) Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology 19, 735-742.
88. Kawashima H, Hirose M, Hirose J, Nagakubo D, Plaas AH, &, Miyasaka M, (2000) Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. J Biol Chem 275, 35448-35456.
89. Monzavi-Karbassi B, Stanley JS, Hennings L, Jousheghany F, Artaud C, Shaaf S, &, Kieber-Emmons T, (2007) Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int J Cancer 120, 1179-1191.
90. Gialeli Ch, Theocharis AD, &, Karamanos NK, (2011) Matrix metalloproteinases in health and disease: roles in cancer progression and their pharmacological targeting. FEBS J 278, 16-27.
91. Iida J, Wilhelmson KL, Ng J, Lee P, Morrison C, Tam E, Overall CM, &, McCarthy JB, (2007) Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J 403, 553-563.
92. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, &, McCarthy JB, (2009) Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res 69, 7538-7547.
93. Fthenou E, Zafiropoulos A, Tsatsakis A, Stathopoulos A, Karamanos NK, &, Tzanakakis GN, (2006) Chondroitin sulfate A chains enhance platelet derived growth factor-mediated signalling in fibrosarcoma cells. Int J Biochem Cell Biol 38, 2141-2150.
94. Fthenou E, Zafiropoulos A, Katonis P, Tsatsakis A, Karamanos NK, &, Tzanakakis GN, (2008) Chondroitin sulfate prevents platelet derived growth factor-mediated phosphorylation of PDGF-Rβ in normal human fibroblasts severely impairing mitogenic responses. J Cell Biochem 103, 1866-1876.
95. Fthenou E, Zong F, Zafiropoulos A, Dobra K, Hjerpe A, &, Tzanakakis GN, (2009) Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. In Vivo 23, 69-76.
96. Nikitovic D, Zafiropoulos A, Tzanakakis GN, Karamanos NK, &, Tsatsakis AM, (2005) Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions. Anticancer Res 25, 2851-2856.
97. Zafiropoulos A, Fthenou E, Chatzinikolaou G, &, Tzanakakis GN, (2008) Glycosaminoglycans and PDGF signaling in mesenchymal cells. Connect Tissue Res 49, 153-156.
98. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, &, Horsfall DJ, (2002) Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8, 1054-1060.
99. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, &, Horsfall DJ, (1998) Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 4, 963-971.
100. Skandalis SS, Kletsas D, Kyriakopoulou D, Stavropoulos M, &, Theocharis DA, (2006) The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim Biophys Acta 1760, 1217-1225.
101. Theocharis AD, Vynios DH, Papageorgakopoulou N, Skandalis SS, &, Theocharis DA, (2003) Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 35, 376-390.
102. Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis AD, Karamanos NK, &, Tzanakakis GN, (2006) Transforming growth factor-β as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 58, 47-53.
103. Iozzo RV, &, Schaefer L, (2011) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 3864-3875.
104. Zafiropoulos A, Nikitovic D, Katonis P, Tsatsakis A, Karamanos NK, &, Tzanakakis GN, (2008) Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells. Mol Cancer Res 6, 785-794.
105. Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A, et al. (2006) Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem 281, 35116-35128.
106. Skliris A, Happonen KE, Terpos E, Labropoulou V, Børset M, Heinegørd D, Blom AM, &, Theocharis AD, (2011) Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur J Immunol 41, 437-449.
107. Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, Papageorgakopoulou N, Stavropoulos MS, &, Vynios DH, (2011) Chondroitin synthases I, II, III and chondroitin sulfate glucuronyltransferase expression in colorectal cancer. Mol Med Report 4, 363-368.
108. Bret C, Hose D, Reme T, Sprynski AC, Mahtouk K, Schved JF, Quittet P, Rossi JF, Goldschmidt H, &, Klein B, (2009) Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol 145, 350-368.
109. Potapenko IO, Haakensen VD, Luders T, Helland A, Bukholm I, Sorlie T, Kristensen VN, Lingjaerde OC, &, Borresen-Dale AL, (2010) Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol 4, 98-118.
110. Pumphrey CY, Theus AM, Li S, Parrish RS, &, Sanderson RD, (2002) Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 62, 3722-3728.
111. Kawashima H, Atarashi K, Hirose M, Hirose J, Yamada S, Sugahara K, &, Miyasaka M, (2002) Oversulfated chondroitin/dermatan sulfates containing GlcAβ1/IdoAα1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines. J Biol Chem 277, 12921-12930.
112. Borsig L, Wang L, Cavalcante MC, Cardilo-Reis L, Ferreira PL, Mourão PA, Esko JD, &, Pavão MS, (2007) Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem 282, 14984-14991.
113. Purushothaman A, Fukuda J, Mizumoto S, ten Dam GB, van Kuppevelt TH, Kitagawa H, Mikami T, &, Sugahara K, (2007) Functions of chondroitin sulfate/dermatan sulfate chains in brain development. Critical roles of E and iE disaccharide units recognized by a single chain antibody GD3G7. J Biol Chem 282, 19442-19452.
114. Ten Dam GB, Yamada S, Kobayashi F, Purushothaman A, van de Westerlo EM, Bulten J, Malmström A, Sugahara K, Massuger LF, &, van Kuppevelt TH, (2009) Dermatan sulfate domains defined by the novel antibody GD3A12, in normal tissues and ovarian adenocarcinomas. Histochem Cell Biol 132, 117-127.
115. Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo KO, Planagumà J, Reed RK, Bjerkvig R, Miletic H, Enger PO, et al. (2011) Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS ONE 6, e23062.
116. Couchman JR, Caterson B, Christner JE, &, Baker JR, (1984) Mapping by monoclonal antibody detection of glycosaminoglycans in connective tissues. Nature 307, 650-652.
117. Calabro A, Hascall VC, &, Caterson B, (1992) Monoclonal antibodies directed against epitopes within the core protein structure of the large aggregating proteoglycan (aggrecan) from the swarm rat chondrosarcoma. Arch Biochem Biophys 298, 349-360.
118. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, &, Miyasaka M, (2002) Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62, 4282-4288.
119. Pathak A, Kumar P, Chuttani K, Jain S, Mishra AK, Vyas SP, &, Gupta KC, (2009) Gene expression, biodistribution, and pharmacoscintigraphic evaluation of chondroitin sulfate-PEI nanoconstructs mediated tumor gene therapy. ACS Nano 3, 1493-1505.
120. Patel M, Shah T, &, Amin A, (2007) Therapeutic opportunities in colon-specific drug-delivery systems. Crit Rev Ther Drug Carrier Syst 24, 147-202.
121. Amrutkar JR, &, Gattani SG, (2009) Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin. AAPS PharmSciTech 10, 670-677.
122. Martins JR, Gadelha ME, Fonseca SM, Sampaio LO, De L, Pontes PA, Dietrich CP, &, Nader HB, (2000) Patients with head and neck tumors excrete a chondroitin sulfate with a low degree of sulfation: a new tool for diagnosis and follow-up of cancer therapy. Otolaryngol Head Neck Surg 122, 115-118.
123. Weigel PH, &, DeAngelis PL, (2007) Hyaluronan synthases: a decade-plus of novel glycosyltransferases. J Biol Chem 282, 36777-36781.
124. Vigetti D, Genasetti A, Karousou E, Viola M, Moretto P, Clerici M, Deleonibus S, De Luca G, Hascall VC, &, Passi A, (2011) Proinflammatory cytokines induce hyaluronan synthesis and monocytes adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the nuclear factor-κB (NF-κB) pathway. J Biol Chem 285, 24639-24645.
125. Towler MC, &, Hardie DG, (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100, 328-341.
126. Vigetti D, Clerici M, Deleonibus S, Karousou E, Viola M, Moretto P, Heldin P, Hascall VC, De Luca G, &, Passi A, (2011) Hyaluronan synthesis is inhibited by adenosine monophosphate-activated protein kinase through the regulation of HAS2 activity in human aortic smooth muscle cells. J Biol Chem 286, 7917-7924.
127. Karousou E, Kamiryo M, Skandalis SS, Ruusala A, Asteriou T, Passi A, Yamashita H, Hellman U, Heldin CH, &, Heldin P, (2010) The activity of hyaluronan synthase 2 is regulated by dimerization and ubiquitination. J Biol Chem 285, 23647-23654.
128. Toole BP, (2001) Hyaluronan in morphogenesis. Semin Cell Dev Biol 12, 79-87.
129. Turley EA, Noble PW, &, Bourguignon LY, (2002) Signaling properties of hyaluronan receptors. J Biol Chem 277, 4589-4592.
130. Jackson DG, (2009) Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol Rev 230, 216-231.
131. Kouvidi K, Berdiaki A, Nikitovic D, Katonis P, Afratis N, Hascall VC, Karamanos NK, &, Tzanakakis GN, (2011) Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J Biol Chem 286, 38509-38520.
132. Stern R, (2008) Hyaluronidases in cancer biology. Semin Cancer Biol 18, 275-280.
133. Tammi RH, Passi AG, Rilla K, Karousou E, Vigetti D, Makkonen K, &, Tammi MI, (2011) Transcriptional and post-translational regulation of hyaluronan synthesis. FEBS J 278, 1419-1428.
134. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, &, Kosma VM, (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156, 529-536.
135. Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen J, Johansson R, Böhm J, Hollmén S, &, Kosma VM, (2001) Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 95, 12-17.
136. Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, Saarikoski SV, &, Kosma VM, (2000) High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60, 150-155.
137. Kosunen A, Ropponen K, Kellokoski J, Pukkila M, Virtaniemi J, Valtonen H, Kumpulainen E, Johansson R, Tammi R, Tammi M, et al. (2004) Reduced expression of hyaluronan is a strong indicator of poor survival in oral squamous cell carcinoma. Oral Oncol 40, 257-263.
138. Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ, Alhava EM, &, Kosma VM, (2000) Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 157, 957-965.
139. Heldin P, Delatorre M, Ytterberg D, &, Bergh J, (1996) Differential synthesis and binding of hyaluronan by human breast cancer cell lines. Oncol Rep 3, 1011-1016.
140. Toole BP, (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4, 528-539.
141. Bourguignon LY, Singleton PA, Zhu H, &, Diedrich F, (2003) Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 278, 29420-29434.
142. Ponta H, Sherman L, &, Herrlich P, (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4, 33-45.
143. Udabage L, Brownlee GR, Nilsson SK, &, Brown TJ, (2005) The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 310, 205-217.
144. Adamia K, Reiman T, Crainie M, Mant MJ, Belch AR, &, Pilarski LM, (2005) Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood 105, 4836-4844.
145. Jacobson A, Rahmanian M, Rubin K, &, Heldin P, (2002) Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 102, 212-219.
146. Lokeshwar VB, Lokeshwar BL, Pham HT, &, Block NL, (1996) Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate
147. Lokeshwar VB, Cerwinka WH, Isoyama T, &, Lokeshwar BL, (2005) HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 65, 7782-7789.
148. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, et al. (2002) Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160, 441-447.
149. Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H, &, Miyasaka M, (2003) Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem 278, 32259-32265.
150. Matou-Nasri S, Gaffney J, Kumar S, &, Slevin M, (2009) Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. Int J Oncol 35, 761-773.
151. Takahashi Y, Li L, Kamiryo M, Asteriou T, Moustakas A, Yamashita H, &, Heldin P, (2005) Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GRO1-dependent manner. J Biol Chem 280, 24195-24204.
152. Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, &, Lokeshwar VB, (2003) Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 106, 438-445.
153. Nemec RE, Toole BP, &, Knudson W, (1987) The cell surface hyaluronate binding sites of invasive human bladder carcinoma cells. Biochem Biophys Res Commun 149, 249-257.
154. Zeng C, Toole BP, Kinney SD, Kuo JW, &, Stamenkovic I, (1998) Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77, 396-401.
155. Ghatak S, Misra S, &, Toole BP, (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277, 38013-38020.
156. Xu H, Ito T, Tawada A, Maeda H, Yamanokuchi H, Isahara K, Yoshida K, Uchiyama Y, &, Asari A, (2002) Effect of hyaluronan oligosaccharides on the expression of heat shock protein 72. J Biol Chem 277, 17308-17314.
157. Urakawa H, Nishida Y, Knudson W, Knudson CB, Arai E, Kozawa E, Futamura N, Wasa J, &, Ishiguro N, (2011) Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer. J Orthop Res 30, 662-672.
158. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, &, McDonald JA, (2002) Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 8, 850-855.
159. Itano N, Atsumi F, Sawai T, Yamada Y, Miyaishi O, Senga T, Hamaguchi M, &, Kimata K, (2002) Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci USA 99, 3609-3614.
160. Balkwill F, &, Mantovani A, (2001) Inflammation and cancer: back to Virchow? Lancet 357, 539-545.
161. Coussens LM, &, Werb Z, (2002) Inflammation and cancer. Nature 420, 860-867.
162. Hallgren R, Gerdin B, &, Tufveson G, (1990) Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft. Relationship to the transplantation edema. J Exp Med 171, 2063-2076.
163. Tufveson G, Gerdin B, Larsson E, Laurent T, Wallander J, Wells A, &, Hallgren R, (1992) Hyaluronic acid accumulation; the mechanism behind graft rejection edema. Transpl Int 5, S688-S689.
164. Huh JW, Choi MM, Yang SJ, Yoon SY, Choi SY, &, Cho SW, (2005) Inhibition of human UDP-glucose dehydrogenase expression using siRNA expression vector in breast cancer cells. Biotechnol Lett 27, 1229-1232.
165. Campbell RE, &, Tanner ME, (1999) UDP-glucose analogues as inhibitors and mechanistic probes of UDP-glucose dehydrogenase. J Org Chem 64, 9487-9492.
166. Hwang EY, Huh JW, Choi MM, Choi SY, Hong N, &, Cho SW, (2008) Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity. FEBS Lett 582, 3793-3797.
167. Kudo D, Kon A, Yoshihara S, Kakizaki I, Sasaki M, Endo M, &, Takagaki K, (2004) Effect of a hyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell adhesion and locomotion. Biochem Biophys Res Commun 321, 783-787.
168. Yoshihara S, Kon A, Kudo D, Nakazawa H, Kakizaki I, Sasaki M, Endo M, &, Takagaki K, (2005) A hyaluronan synthase suppressor, 4- methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett 579, 2722-2726.
169. Arai E, Nishida Y, Wasa J, Urakawa H, Zhuo L, Kimata K, Kozawa E, Futamura N, &, Ishiguro N, (2011) Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer 105, 1839-1849.
170. Piccioni F, Malvicini M, Garcia MG, Rodriguez A, Atorrasagasti C, Kippes N, Buena IT, Rizzo MM, Bayo J, Aquino J, et al. (2012) Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology 22, 400-410.
171. Misra S, Hascall VC, De Giovanni C, Markwald RR, &, Ghatak S, (2009) Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ mice. J Biol Chem 284, 12432-12446.
172. Song G, Liao X, Zhou L, Wu L, Feng Y, &, Han ZC, (2004) HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leuk Res 28, 1089-1096.
173. Platt VM, &, Szoka FC Jr, (2008) Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5, 474-486.
174. Orian-Rousseau V, &, Ponta H, (2008) Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Adv Cancer Res 101, 63-92.
175. Eliaz RE, &, Szoka FC Jr, (2001) Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 61, 2592-2601.
176. Luo Y, Ziebell MR, &, Prestwich GD, (2000) A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 1, 208-218.
177. Akima K, Ito H, Iwata Y, Matsuo K, Watari N, Yanagi M, Hagi H, Oshima K, Yagita A, Atomi Y, et al. (1996) Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J Drug Target 4, 1-8.
178. Karamanos NK, &, Tzanakakis GN, (2012) Glycosaminoglycans: from 'cellular glue' to novel therapeutical agents. Curr Opin Pharmacol, doi:.